Thalidomide for severe systemic onset juvenile rheumatoid arthritis: A multicenter study.
Thirteen children with difficult systemic onset juvenile rheumatoid arthritis were treated with thalidomide. At 6 months, 11 of the 13 were able to reduce their use of prednisone ( P < .002), with a concurrent improvement in erythrocyte sedimentation rate ( P < .0001) and an increase in hemoglobin level ( P < 0.005). Juvenile rheumatoid arthritis improvement scores >/=50% were obtained by 10 of the 13 children.
Lehman
Thomas J A
TJ
Division of Pediatric Rheumatology, Hospital for Special Surgery, and the Department of Pediatrics, Sanford Weill Medical College of Cornell University, New York, New York, USA.
Schechter
Sharon J
SJ
Sundel
Robert P
RP
Oliveira
Sheila K
SK
Huttenlocher
Anna
A
Onel
Karen B
KB
D001171:Arthritis, Juvenile / Q000188:drug therapy*; D001799:Blood Sedimentation / Q000187:drug effects; D002648:Child; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D013792:Thalidomide / Q000627:therapeutic use*; D016896:Treatment Outcome
D007166:Immunosuppressive Agents; D013792:Thalidomide